Royalty Pharma plc Appoints Eric Schneider as CTO
Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma’s Senior Leadership...
-
-
Ascendis Pharma and Royalty Pharma Enter $150M Royalty Funding Agreement
Ascendis Pharma A/S (Nasdaq: NASDAQ:ASND) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Ascendis has entered into a $150 million capped synthetic royalty funding agreement with...
-
Royalty Pharma plc and Ferring Pharmaceuticals Enter $500M Royalty Agreement for New Intravesical Gene Therapy Adstiladrin
Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals today announced that Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring’s Adstiladrin® (nadofaragene...
-
UBS maintains Royalty Pharma at 'buy' with a price target of $41.00
An analyst from UBS maintained Royalty Pharma (NASDAQ: RPRX) at 'buy' with a price target of $41.00 from a prior price target of %currency%%price%. Prior to this rating, Royalty Pharma had...
-
Morgan Stanley maintains Royalty Pharma at 'overweight' with a price target of $53.00
An analyst from Morgan Stanley maintained Royalty Pharma (NASDAQ: RPRX) at 'overweight' with a price target of $53.00 from a prior price target of %currency%%price%. Prior to this rating,...
-
Royalty Pharma earnings missed by $0.45, revenue fell short of estimates
Investing.com - Royalty Pharma (NASDAQ: RPRX) reported second quarter EPS of $0.38, $0.45 worse than the analyst estimate of $0.83. Revenue for the quarter came in at $541.81M versus the...
-
UBS maintains Royalty Pharma at 'buy' with a price target of $44.00
An analyst from UBS maintained Royalty Pharma (NASDAQ: RPRX) at 'buy' with a price target of $44.00 from a prior price target of %currency%%price%. Prior to this rating, Royalty Pharma had...
-
Royalty Pharma plc CEO buys nearly $5 million in stock
Late Wednesday, Royalty Pharma plc (RPRX) CEO/Chairman, Pablo Legorreta, disclosed the purchase of 150,000 common shares made on 05/24/23 at $32.2496.The value of the purchase was nearly $5...
-
Morgan Stanley maintains Royalty Pharma at 'overweight' with a price target of $52.00
An analyst from Morgan Stanley maintained Royalty Pharma (NASDAQ: RPRX) at '' 'overweight' and a price target of $52.00 from a prior price target of %currency%%price%. Prior to this rating,...
-
Royalty Pharma earnings missed by $0.59, revenue fell short of estimates
Investing.com - Royalty Pharma (NASDAQ: RPRX) reported first quarter EPS of $0.56, $0.59 worse than the analyst estimate of $1.15. Revenue for the quarter came in at $684M versus the...
-
Morgan Stanley maintains Royalty Pharma at Overweight
A Morgan Stanley analyst maintained Royalty Pharma (NASDAQ: RPRX) at Overweight and a price target of $50.00 from a prior price target of %currency%%price%. Prior to this rating, Royalty...
-
Royalty Pharma plc Announces $1B Share Buyback
Royalty Pharma plc (Nasdaq: RPRX) today announced that the company’s Board of Directors has authorized the repurchase of up to $1.0 billion of the company’s Class A ordinary shares. Royalty...
-
Royalty Pharma and PureTech Health Enter KarXT Royalty Agreement for Up to $500M
Royalty Pharma plc (Nasdaq: RPRX), the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the life sciences industry, and PureTech Health plc (Nasdaq:...
-
Royalty Pharma Raises Full Year 2023 Guidance
Royalty Pharma plc (Nasdaq: RPRX) today announced that it has received a $475 million accelerated milestone payment from Pfizer, following the U.S. Food and Drug Administration (FDA)...
-
In case you missed it, 4 big dividend hikes: Wendy's doubles payout
By Davit Kirakosyan Investing.com -- Among the 4 biggest recent dividend hikes and special dividends, Wendy's hiked its payout by 100%, while also announcing it would repurchase up to a...
-
3 big dividend moves: Royalty Pharma, EMCOR
Here are 3 big dividend hikes to start the week, all covered in real time on InvestingPro. Royalty Pharma Plc (NASDAQ:RPRX) hiked its quarterly dividend by 5.3% to $0.20 per share, or...
-
Royalty Pharma earnings, Revenue miss in Q3
Investing.com - Royalty Pharma reported on Tuesday third quarter {{erl-1162162||earnings that missed analysts' forecasts and revenue that fell short of expectations. Royalty Pharma...
-
Royalty Pharma plc reports Q3 results; Offers Guidance
Royalty Pharma plc (RPRX) reported Q3 resutls. Revenue for the quarter came in at $573 million versus the consensus estimate of $584.92 million.GUIDANCE:Adjusted Cash Receipts expected to be...
-
Royalty Pharma plc Tops Q2 Revenue Estimate
Royalty Pharma plc (RPRX) reported Q2 cash receipts of $536 million versus the consensus estimate of $532.56 million.GUIDANCE:Royalty Pharma plc sees FY2022 adjusted cash receipts...
-
Walmart, Home Depot Rise Premarket; Tesla, Pfizer Fall
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Tuesday, November 16th. Please refresh for updates. Walmart (NYSE:WMT) stock rose 0.7% after the retail giant raised...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
